Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

Cancer is the second cause of death worldwide, surpassed only by cardiovascular diseases, due to the lack of early diagnosis, and high relapse rate after conventional therapies. Chemotherapy inhibits the rapid growth of cancer cells, but it also affects normal cells with fast proliferation rate. The...

Full description

Bibliographic Details
Main Authors: Mariela Montaño-Samaniego, Diana M. Bravo-Estupiñan, Oscar Méndez-Guerrero, Ernesto Alarcón-Hernández, Miguel Ibáñez-Hernández
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.605380/full
id doaj-918b6fcc1a4547f6bd0df65058a87491
record_format Article
spelling doaj-918b6fcc1a4547f6bd0df65058a874912020-12-14T06:31:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-12-011010.3389/fonc.2020.605380605380Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific PromotersMariela Montaño-Samaniego0Diana M. Bravo-Estupiñan1Oscar Méndez-Guerrero2Ernesto Alarcón-Hernández3Miguel Ibáñez-Hernández4Laboratorio de Terapia Génica, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Ciudad de México, MéxicoLaboratorio de Terapia Génica, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Ciudad de México, MéxicoLaboratorio de Terapia Génica, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Ciudad de México, MéxicoLaboratorio de Genética Molecular, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Ciudad de México, MéxicoLaboratorio de Terapia Génica, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional, Ciudad de México, MéxicoCancer is the second cause of death worldwide, surpassed only by cardiovascular diseases, due to the lack of early diagnosis, and high relapse rate after conventional therapies. Chemotherapy inhibits the rapid growth of cancer cells, but it also affects normal cells with fast proliferation rate. Therefore, it is imperative to develop other safe and more effective treatment strategies, such as gene therapy, in order to significantly improve the survival rate and life expectancy of patients with cancer. The aim of gene therapy is to transfect a therapeutic gene into the host cells to express itself and cause a beneficial biological effect. However, the efficacy of the proposed strategies has been insufficient for delivering the full potential of gene therapy in the clinic. The type of delivery vehicle (viral or non viral) chosen depends on the desired specificity of the gene therapy. The first gene therapy trials were performed with therapeutic genes driven by viral promoters such as the CMV promoter, which induces non-specific toxicity in normal cells and tissues, in addition to cancer cells. The use of tumor-specific promoters over-expressed in the tumor, induces specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several cancer- and/or tumor-specific promoters systems have been developed to target cancer cells. This review aims to provide up-to-date information concerning targeting gene therapy with cancer- and/or tumor-specific promoters including cancer suppressor genes, suicide genes, anti-tumor angiogenesis, gene silencing, and gene-editing technology, as well as the type of delivery vehicle employed. Gene therapy can be used to complement traditional therapies to provide more effective treatments.https://www.frontiersin.org/articles/10.3389/fonc.2020.605380/fullcancergene therapytargeted treatmentspecific promotersnon-viral vectors
collection DOAJ
language English
format Article
sources DOAJ
author Mariela Montaño-Samaniego
Diana M. Bravo-Estupiñan
Oscar Méndez-Guerrero
Ernesto Alarcón-Hernández
Miguel Ibáñez-Hernández
spellingShingle Mariela Montaño-Samaniego
Diana M. Bravo-Estupiñan
Oscar Méndez-Guerrero
Ernesto Alarcón-Hernández
Miguel Ibáñez-Hernández
Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
Frontiers in Oncology
cancer
gene therapy
targeted treatment
specific promoters
non-viral vectors
author_facet Mariela Montaño-Samaniego
Diana M. Bravo-Estupiñan
Oscar Méndez-Guerrero
Ernesto Alarcón-Hernández
Miguel Ibáñez-Hernández
author_sort Mariela Montaño-Samaniego
title Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
title_short Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
title_full Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
title_fullStr Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
title_full_unstemmed Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
title_sort strategies for targeting gene therapy in cancer cells with tumor-specific promoters
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2020-12-01
description Cancer is the second cause of death worldwide, surpassed only by cardiovascular diseases, due to the lack of early diagnosis, and high relapse rate after conventional therapies. Chemotherapy inhibits the rapid growth of cancer cells, but it also affects normal cells with fast proliferation rate. Therefore, it is imperative to develop other safe and more effective treatment strategies, such as gene therapy, in order to significantly improve the survival rate and life expectancy of patients with cancer. The aim of gene therapy is to transfect a therapeutic gene into the host cells to express itself and cause a beneficial biological effect. However, the efficacy of the proposed strategies has been insufficient for delivering the full potential of gene therapy in the clinic. The type of delivery vehicle (viral or non viral) chosen depends on the desired specificity of the gene therapy. The first gene therapy trials were performed with therapeutic genes driven by viral promoters such as the CMV promoter, which induces non-specific toxicity in normal cells and tissues, in addition to cancer cells. The use of tumor-specific promoters over-expressed in the tumor, induces specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several cancer- and/or tumor-specific promoters systems have been developed to target cancer cells. This review aims to provide up-to-date information concerning targeting gene therapy with cancer- and/or tumor-specific promoters including cancer suppressor genes, suicide genes, anti-tumor angiogenesis, gene silencing, and gene-editing technology, as well as the type of delivery vehicle employed. Gene therapy can be used to complement traditional therapies to provide more effective treatments.
topic cancer
gene therapy
targeted treatment
specific promoters
non-viral vectors
url https://www.frontiersin.org/articles/10.3389/fonc.2020.605380/full
work_keys_str_mv AT marielamontanosamaniego strategiesfortargetinggenetherapyincancercellswithtumorspecificpromoters
AT dianambravoestupinan strategiesfortargetinggenetherapyincancercellswithtumorspecificpromoters
AT oscarmendezguerrero strategiesfortargetinggenetherapyincancercellswithtumorspecificpromoters
AT ernestoalarconhernandez strategiesfortargetinggenetherapyincancercellswithtumorspecificpromoters
AT miguelibanezhernandez strategiesfortargetinggenetherapyincancercellswithtumorspecificpromoters
_version_ 1724383834336657408